PROF 7.64 Stock Price Profound Medical Corp.
Range: | 7.11-11.42 | Vol Avg: | 48237 | Last Div: | 0 | Changes: | 0.03 |
Beta: | 0.83 | Cap: | 0.19B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Tue Oct 29 2019 | Empoloyees: | 131 |
CUSIP: | 74319B502 | CIK: | 0001628808 | ISIN: | CA74319B5027 | Country: | CA |
CEO: | Dr. Arun Swarup Menawat MBA, Ph.D. | Website: | https://www.profoundmedical.com |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.